Slide 1: Prevest DenPro submission of investor presentation to BSE
-W ?REVESTDenPro® I'\. THE FUTURE OF DENTISTRY August 11, 2022 To The Secretary, Listing Department BSE Limited(SME), Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 00 I Dear Sir, Sub: Submission of Investor Presentation to be made to Analysts/Investors Please find enclosed herewith the i
Slide 2: Earnings Presentation Q1FY23
Setting standards in dental care EARNINGS PRESENTATION Q1FY23
Slide 3: Prevest - at a glance
Prevest - at a glance With over 22 years of experience in development, manufacture and sale of innovative materials for dental professionals, Prevest DenPro Limited is one of the India’s leading manufacturer of dental materials serving the global dental market with a wide range of high quality denta
Slide 4: Comprehensive product portfolio
Comprehensive product portfolio 3
Slide 5: Comprehensive Product Portfolio
Comprehensive Product Portfolio Product Categories No. of products Product Usage Endodontics Materials +25 Root canal treatment Cements & Liners +16 Luting and restorative applications Composites +8 Dental restoration and filling Orthodontics Materials +2 Used for Orthodontic applications Finishing
Slide 6: Production and R&D facility
Production and R&D facility Products are developed, manufactured and assembled in-house at Company’s Manufacturing unit located at EPIP Kartholi, Samba, near Jammu, J&K, sprawling in an area of 45,000 sq. ft. 5
Slide 7: Diversification in new product segments
Diversification in new product segments Bio-materials Medicated ointments, Mouth washes and Disinfectants and (Bone grafting materials gels and creams for Mouth rinses Sanitizers and membranes) dental treatment New Facility under construction for manufacturing new range of products › The Company see
Slide 8: Global presence
Global presence GEOGRAPHICAL WISE REVENUE FROM OPERATIONS DIGITAL MARKET PLATFORMS FY2022 10%5% 1% 18% TOTAL RS. 3762 LAKHS 12% 54% Africa Asia Europe Middle East Export to +90 +55 › Products sold in over 80 countries worldwide. over › Exploring the markets of USA , Brazil and Canada. Overseas Deale
Slide 9: Strategic technical & research tie-ups
Strategic technical & research tie-ups The Company has entered into collaboration with the following reputed dental universities & institutions for exchange of technical knowledge and conducting training & research on dental materials. The Company has also entered into technology transfer agreement
Slide 10: Quality accreditations
Quality accreditations With a focus on product quality, the company has successfully implemented a very effective quality management system which has been approved by TUV SUD, Germany. With the strong quality management system, all production processes are subjected to stringent monitoring and inten
Slide 11: Competitive strengths
Competitive strengths Well - established sales B2B and B2C Comprehensive Product Research Collaboration Strong Advisory Board network in over 80 Sales Model Portfolio with prominent & Management Countries academic institutes With consistent marketing Along with B2B Sales (i.e. In the last two decade
Slide 12: Board of Directors
Board of Directors Our Board of Directors is responsible for corporate governance, establishing policies and objectives, and management of the company’s resources. The Board is firmly committed to upholding high standards of corporate governance. Atul Modi Namrata Modi Dr. Sai Kalyan Surapaneni (Cha
Slide 13: Advisory Board
Advisory Board The company is honored to have industry recognized and esteemed dental professionals, scientists and researchers on Advisory Board to augment the knowledge, understanding and strategic thinking of the Board members and management team as well as to provide expert insights in the denta
Slide 14: Operational strategies
Operational strategies Development of R&D Centre Enter into high growth markets The Company intends to strengthen its R&D The Company is all set to mark footprints in the capabilities by setting up a state-of-the-art markets of USA, Canada and Brazil. The Company research & development center for th
Slide 15: Awards and recognitions
Awards and recognitions We are honored to be recognized as a leading manufacturer of quality dental materials, for excellent financial performance, creating brand value and reputations within India and across the globe. We have received Export Excellence Award from Federation of Indian Exporters Org
Slide 16: Key growth drivers in dental industry
Key growth drivers in dental industry The major factors favoring the dental market growth are increasing number of patients, with the dental caries, and periodontal diseases, which is boosting the demand for the dental materials. According to the study of the Global Burden of Disease Study, in 2017,
Slide 17: Outlook of Indian dental industry
Outlook of Indian dental industry GROWTH IN DENTAL TOURISM - India is able to spur its growth momentum in dental tourism with the implementation of advanced technology to perform procedures like implant surgery, cosmetic dentistry, orthodontics and paediatric dentistry ensuring high quality standard
Slide 18: Financial Overview
FINANCIAL OVERVIEW 17
Slide 19: Quarter highlights
Quarter highlights Q4FY22 Vs Q1FY23 Financial Highlights for Q1FY23 Vs Q4FY22: 1298.38 1019.32 • Reported total Revenue at Rs 1298.38 lakhs in Q1FY23 Vs Rs 1019.32 in Q4FY22 which has grown by 27.38%. • Company reported EBITDA at Rs 519.44 lakhs in 519.44 Q1FY23 Vs Rs. 376.70 lakhs in Q4FY22 which h
Slide 20: Exponential growth in revenue and profitability
Exponential growth in revenue and profitability EBITDA* TOTAL REVENUE* CAGR 48% CAGR 22.6% 3,973.50 1,667.99 2,951.35 999.42 2,455.97 1,977.08 689.22 1,758.20 430.92 348.61 2017-18 2018-19 2019-20 2020-21 2021-22 2017-18 2018-19 2019-20 2020-21 2021-22 PAT* EPS (IN RS.) CAGR 52% 1156.88 9.64 8.16 72
Slide 21: Key ratios: on a continuous financial growth
Key ratios: on a continuous financial growth PAT MARGIN EBITDA MARGIN 29.11% 41.98% 24.42% 33.86% 20.39% 28.06% 15.14% 19.83% 21.80% 12.35% 6.55% 8.77% 13.33% 14.96% 2015-16 2016-17 2017-18 2018-19 2019-20 2020-21 2021-22 2015-16 2016-17 2017-18 2018-19 2019-20 2020-21 2021-22 DEBT EQUITY RATIO RETU
Slide 22: Immense value creation with negligible debt
Immense value creation with negligible debt NET WORTH* OPERATING CASH FLOWS* 5710.45 696.23 472.61 2,249.60 301.00 242.10 1,530.59 189.55 1,029.72 730.34 292.87 422.36 2015-16 2016-17 2017-18 2018-19 2019-20 2020-21 2021-22 2017-18 2018-19 2019-20 2020-21 2021-22 *Rs in Lakhs *Net debt represents to
Slide 23: Statement of profit & loss
Statement of profit & loss PARTICULARS Q1 FY23 (Unaudited) Q4 FY22(Audited) FY22 (Audited) FY21 (Audited) Income From Operation Net Sales / Income from Operation (Net of Taxes) 1,229.99 933.16 3,762.34 2,847.60 Other Income 68.39 86.16 211.15 103.74 Total Revenue 1,298.38 1,019.32 3,973.50 2,951.35
Slide 24: Balance sheet - assets
Balance sheet - assets ASSETS 3/31/2022 (Audited) 3/31/2021 (Audited) Non- Current Assets Property, Plant & Equipment and Intangible Assets - - Property, Plant & Equipment 671.89 536.23 Capital Works in progress 472.15 171.13 Total 1,144.04 707.35 Current Assets Current Investment 72.90 43.80 Invent
Slide 25: Balance sheet – liabilities
Balance sheet – liabilities EQUITY & LIABILITIES 3/31/2022 (Audited) 3/31/2021 (Audited) Shareholders Funds Share Capital 1,200.30 28.50 Reserves & Surplus 4,510.15 2,221.10 Total 5,710.45 2,249.60 Non- current Liabilities Long- Term Borrowings 136.67 139.39 Deferred Tax Liabilities (Net) 28.89 24.0
Slide 26: Disclaimer
Disclaimer This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute prospectus or placement memorandum or an offer to acquire any securities. No representation or warranty, express or implied is made as to, and no reli